Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 Months in Prepubertal Children With Achondroplasia

Trial Profile

ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 Months in Prepubertal Children With Achondroplasia

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TransCon CNP (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms ACcomplisH
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 12 Jan 2020 According to an Ascendis Pharma media release, company plans to escalate sequential dose cohorts throughout 2020.
    • 18 Jul 2019 According to an Ascendis Pharma media release, the company expects to enroll the first subject in this study later in 2019.
    • 18 Jul 2019 According to an Ascendis Pharma media release, the company announces filing of an investigational new drug(IND) application with the U.S. Food and Drug Administration (FDA) to initiate this global phase 2 study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top